These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21268434)

  • 1. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?
    Sznol M
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1340-1. PubMed ID: 21268434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable disease is a valid end point in clinical trials.
    Tolcher AW
    Cancer J; 2009; 15(5):374-8. PubMed ID: 19826356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic response in phase I trials of antineoplastic agents.
    Estey E; Hoth D; Simon R; Marsoni S; Leyland-Jones B; Wittes R
    Cancer Treat Rep; 1986 Sep; 70(9):1105-15. PubMed ID: 3527410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Tian C; Bookman MA
    Gynecol Oncol; 2010 May; 117(2):324-9. PubMed ID: 20185168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological aspects of lung cancer clinical trials in the era of targeted agents.
    Di Maio M; Gallo C; De Maio E; Morabito A; Piccirillo MC; Gridelli C; Perrone F
    Lung Cancer; 2010 Feb; 67(2):127-35. PubMed ID: 19875193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II stopping rules that employ response rates and early progression.
    Goffin JR; Tu D
    J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
    Bradbury P; Seymour L
    Cancer J; 2009; 15(5):354-60. PubMed ID: 19826353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer.
    Arkenau HT; Nordman I; Dobbins T; Ward R
    Cancer; 2011 Feb; 117(4):832-40. PubMed ID: 20886631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.